Penumbra Q3 revenue $301M (+11.1% YoY); U.S. thrombectomy up 21.2%; raises segment guidance

Penumbra Inc

2024-Q3 EPS reported -$0.51 revenue$879,097,000

Revenue $301.0M, +11.1% YoY; net income $29.5M; adjusted EBITDA $56.7M (18.8% margin).
U.S. thrombectomy revenue $162.1M, +21.2% YoY; VTE franchise grew 32% vs Q3 2023.
GAAP operating income $35.4M vs $12.6M in Q3 2023; non-GAAP operating income $40.3M.
Full-year 2024 revenue reaffirmed $1.18-1.20B; U.S. thrombectomy growth expectation raised to 24-25% from 23-25%.
Wind down of Immersive Healthcare incurred $5M in one-time expenses during Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.